industries we serve
BERKELEY LIGHTS’ TECHNOLOGY FUNCTIONALLY SCREENS 1000s OF LIVING CELLS IN MINUTES, HOURS OR DAYS.
drug discoverySpeeding Antibody Discovery >
Drug developmentAdvancing Cell Line Development >
Cell TherapiesTransforming T-Cell Functional Analytics >
Gene EditingImproving Gene Editing >
THE LATEST FROM BERKELEY LIGHTS
Berkeley Lights, Inc. (BLI), the leader in digital cell biology, announced today that Harbour BioMed, a global biopharmaceutical company has acquired the Beacon® Optofluidic platform to implement accelerated workflows for single-cell screening and analysis.
See full press release >
SEE ALL PRESS RELEASES >
Harbour BioMed Integrates the Beacon® Platform to Accelerate Antibody Discovery Berkeley Lights Further Extends into Asian Market
Stop by Booth #1712 to learn more about our new Plasma B Cell Antibody Discovery workflow, or our other workflows including Cell Line Development with new updates that establish 99% monoclonal cell lines in just 5 days.
MORE DETAILS >
SEE ALL EVENTS >